Clinical study on the safety and efficacy of remifentanil combined with propofol in painless gastroscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052992

Enrollment

Unknown

Registered

2021-11-07

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal dysfunction

Interventions

propofol group:intravenous ues of propofol

remifentanil(0.1ug/kg) + propofol group:Intravenous injection of remifentanil (0.1ug/kg )and propofol

remifentanil(0.3ug/kg) + propofol group:Intravenous remifentanil (0.3ug/kg) and propofol

remifentanil(0.5ug/kg) + propofol group:Intravenous remifentanil (0.5ug/kg) and propofol

remifentanil(0.7ug/kg) + propofol group:Intravenous remifentanil (0.7ug/kg) and propofol

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Outpatients proposed to undergo gastroscopy; 2. Aged 18-60 years; 3. ASA Grade I or II; 4. No serious liver or kidney dysfunction; 5. 18.5 <= BMI < 30kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Patients with acute upper gastrointestinal bleeding leading to hemorrhagic shock with unstable blood pressure; 2. Preoperative assessment of potentially difficult airways (history of difficult airways, sleep apnea syndrome, abnormal head and neck mobility, nail-mind spacing less than 6.5 cm, mouth opening less than 3 horizontal fingers, Mallampati grade greater than 3); 3. The presence of airway hyperresponsiveness (asthma, COPD, long-term smoking history); 4. The existence of central nervous system or cardiovascular system diseases (including past or current hypertension, coronary heart disease, heart valve disease, cardiomyopathy, arrhythmia, heart failure, diabetes, stroke, aneurysm); 5. Those who have a history of allergies to research-related drugs; 6. Currently using drugs that may change the pharmacodynamics and pharmacokinetics of the studied drug (including benzodiazepines; other drugs with analgesic effects, such as NSAIDS, tramadol; other a2 Adrenergic agonists, such as clonidine; drugs that affect hemodynamics, such as antihypertensives, digitalis); 7. Have a history of drug or alcohol addiction; 8. Severe anemia; 9. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Effective sedation during diagnosis and treatment;	—

Countries

China

Contacts

Public ContactWang Liwei

Xuzhou Central Hospital

doctorlww@sina.com+86 18952170255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026